Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
VALLDEPERAS, X.; BONILLA, R.; ROMANO, M.R. y CAMARA, J. de la. Use of intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to choroidal rupture. Arch Soc Esp Oftalmol [online]. 2011, vol.86, n.11, pp.380-383. ISSN 0365-6691.
Case report: A 28 year-old male attended our Emergency Department with a traumatic choroidal rupture and macular haemorrhage. After pneumatic displacement of the haemorrhage with C3F8 and tissue plasminogen activator, the haemorrhage was reabsorbed and visual acuity (VA) improved. Three months later the patient presented with decreased VA and a juxtafoveal choroidal neovascularisation (CNV) that was treated with intravitreal bevacizumab. One year after a single bevacizumab injection the CNV remained inactive, with a final VA of 0.5. Discussion: Intravitreal bevacizumab injection is a new and effective treatment for traumatic CNV. In our patient, in contrast to other aetiologies, the CNV needed no more than one Avastin® injection to be inactivated, after one year of follow-up.
Palabras clave : Recombinant tissue plasminogen activator (rTPA); Pneumatic displacement; Submacular haemorrhage; Ocular traumatism; Bevacizumab; Choroidal rupture; Choroidal neovascularisation.